HYSA induced autophagy in hepatocellular carcinoma cells by promoting Beclin 1 expression and inhibiting ERK phosphorylation, indicating HYSA may be a potential therapeutic agent for hepatocellular carcinoma (Chen et al., 2020). Here, MAPK1 is linked to hepatocellular carcinoma.